Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
9.040USD
-0.050-0.55%
Close 11-13 16:00（ET）
315.41MMarket Cap
LossP/E TTM
Benitec Biopharma Inc (BNTC) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Benitec Biopharma Inc in the past month.
Buy
3 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
23.286USD+166.43%
BNTC Analyst Recommendation Trends
In the current month, BNTC has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BNTC average Analyst price target in the last month is 23.286.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
2
3
4
4
4
4
4
4
4
4
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
6
7
7
7
7
BNTC Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, BNTC EPS is projected to reach -0.298 in FY2027Q2, following reported EPS of -0.261 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
FY2027Q3
Forecast
-0.27
-0.27
-0.29
-0.30
-0.32
Actual
-0.24
-0.26
-0.26
--
--
Surprise
+11.67%
+4.04%
+9.42%
--
--
FAQs
What is Benitec Biopharma Inc's price target?
Analysts forecast that Benitec Biopharma Inc's price target is USD 22.17, with the highest forecast at USD 32.00 and the lowest forecast at USD 17.00.
How have Benitec Biopharma IncBNTC's recent earnings per share performed?
The market expectation was USD -0.26, while Benitec Biopharma IncBNTC's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.30.
What is the analyst rating for Benitec Biopharma Inc?
Based on the ratings of Benitec Biopharma Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.